Published in Chem Pharm Bull (Tokyo) on November 01, 2004
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res (2007) 2.80
Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron (2002) 2.15
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.62
Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem (2004) 1.60
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res (2011) 1.40
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett (2007) 1.33
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.15
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs (2011) 1.14
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2007) 1.10
YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol (2011) 1.08
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int J Pharm (2005) 1.06
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics (2012) 1.02
Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun (2012) 1.02
Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta (2005) 0.96
Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATs). Bioorg Med Chem Lett (2003) 0.93
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther (2014) 0.91
Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun (2002) 0.90
A role of androgen receptor protein in cell growth of an androgen-independent prostate cancer cell line. Biosci Biotechnol Biochem (2005) 0.87
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). Invest New Drugs (2014) 0.86
WDR55 is a nucleolar modulator of ribosomal RNA synthesis, cell cycle progression, and teleost organ development. PLoS Genet (2008) 0.85
Direct induction of chondrogenic cells from human dermal fibroblast culture by defined factors. PLoS One (2013) 0.83
RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila. Biosci Biotechnol Biochem (2008) 0.83
Reduction of visceral fat correlates with the decrease in the number of obesity-related cardiovascular risk factors in Japanese with Abdominal Obesity (VACATION-J Study). J Atheroscler Thromb (2012) 0.83
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res (2006) 0.83
Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands. Bioorg Med Chem (2006) 0.82
Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity. Proc Natl Acad Sci U S A (2009) 0.82
N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists. Chem Pharm Bull (Tokyo) (2005) 0.80
Induction of chondrogenic cells from dermal fibroblast culture by defined factors does not involve a pluripotent state. Biochem Biophys Res Commun (2011) 0.80
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist. Vascul Pharmacol (2005) 0.80
Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors. Bioorg Med Chem (2008) 0.80
Thoracoscopic surgery support system using passive RFID marker. Conf Proc IEEE Eng Med Biol Soc (2012) 0.79
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res (2005) 0.79
Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor. Bioorg Med Chem (2005) 0.79
Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand. Bioorg Med Chem (2006) 0.78
Alterations of renal vasopressin V1A and V2 receptors in spontaneously hypertensive rats. Pharmacology (2003) 0.78
Pharmacological evaluation of Shokyo and Kankyo (1). Biol Pharm Bull (2002) 0.78
Ethylnitrosourea-induced thymus-defective mutants identify roles of KIAA1440, TRRAP, and SKIV2L2 in teleost organ development. Eur J Immunol (2009) 0.77
Toward the synthesis of phomoidride D. J Org Chem (2013) 0.77
Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells. Pharmacology (2006) 0.77
YM-201627: an orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett (2005) 0.77
In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. Int J Pharm (2007) 0.77
Retracted Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther (2005) 0.76
Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorg Med Chem (2013) 0.76
Local variation in the content of angiotensin II and arginine vasopressin receptor antagonistic terpenoids in the rhizomes of Alisma orientale. Planta Med (2002) 0.76
Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist. Eur J Pharmacol (2002) 0.75
Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells. J Hypertens (2002) 0.75
Development of a novel marking system for laparoscopic gastrectomy using endoclips with radio frequency identification tags: feasibility study in a canine model. Surg Endosc (2014) 0.75
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors. Biol Pharm Bull (2005) 0.75
Vaulted trans-bis(salicylaldiminato)platinum(II) crystals: heat-resistant, chromatically sensitive platforms for solid-state phosphorescence at ambient temperature. Chemistry (2013) 0.75
Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups. Chem Pharm Bull (Tokyo) (2003) 0.75
Highly phosphorescent crystals of vaulted trans-bis(salicylaldiminato)platinum(II) complexes. J Am Chem Soc (2011) 0.75
Current organic waste recycling and the potential for local recycling through urban agriculture in Metro Manila. Waste Manag Res (2010) 0.75
Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells. Peptides (2002) 0.75
Corrigendum: Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice by inhibiting Sik3. Nat Commun (2016) 0.75
Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents. Bioorg Med Chem (2011) 0.75
Synthesis and pharmacological evaluation of 2-(1-alkylpiperidin-4-yl)-n-[(1r)-1-(4-fluorophenyl)-2-methylpropyl]acetamide Derivatives as Novel Antihypertensive Agents. Chem Pharm Bull (Tokyo) (2012) 0.75
Solid-state emission enhancement in vaulted trans-bis(salicylaldiminato)platinum(II) crystals with halogen functionality. Dalton Trans (2014) 0.75
Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026. Chem Pharm Bull (Tokyo) (2015) 0.75
Stereoselective synthesis of methyl (Z)-(4,4-difluoro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-ylidene)acetate using a dianion Horner-Wadsworth-Emmons reagent. Chem Pharm Bull (Tokyo) (2005) 0.75
Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists. Bioorg Med Chem (2013) 0.75
8-O-cinnamoylneoline, a new alkaloid from the flower buds of Aconitum carmichaeli and its toxic and analgesic activities. Planta Med (2003) 0.75
Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group. Chem Pharm Bull (Tokyo) (2005) 0.75
Synthesis and pharmacological evaluation of 1-alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents. Chem Pharm Bull (Tokyo) (2011) 0.75
Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel antihypertensive agents. Chem Pharm Bull (Tokyo) (2011) 0.75